Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TGTX Stock Chart & Stats
$30.31
$0.31(1.11%)
At close: 4:00 PM EST
$30.31
$0.31(1.11%)
Day’s Range― - ―
52-Week Range$25.28 - $46.48
Previous CloseN/A
Volume723.16K
Average Volume (3M)1.99M
Market Cap
$4.89B
Enterprise Value$4.99B
Total Cash (Recent Filing)$131.58M
Total Debt (Recent Filing)$253.72M
Price to Earnings (P/E)10.9
Beta0.69
Next Earnings
Mar 03, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.43
Shares Outstanding158,759,450
10 Day Avg. Volume2,489,802
30 Day Avg. Volume1,987,695
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)19.67
Price to Sales (P/S)13.29
P/FCF Ratio-107.84
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.38
Enterprise Value/Gross Profit11.00
Enterprise Value/Ebitda43.31
Forecast
1Y Price Target
$42.60Price Target Upside40.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressAnalyst highlights rapid enrollment in the pivotal intravenous and self‑administered subcutaneous trials, with key readouts that could enable label expansion and materially enlarge the drug’s addressable market if positive.
Commercial Expansion And MarketingAnalyst points to planned expansion of the US salesforce, broader TV and digital campaigns, growing hospital channel penetration, and expanded international distribution as catalysts likely to deepen market penetration and increase recurring revenue.
Revenue And GuidanceAnalyst notes increased US revenue guidance and quarter revenues modestly above expectations, indicating stronger commercial traction for Briumvi that could support further upside in the stock.
Bears Say
Concentration And Event‑driven VolatilityAnalyst notes heavy reliance on a single lead product means clinical or regulatory setbacks could disproportionately affect revenue and produce sharp share price volatility around trial readouts and approvals.
Pivotal Study Execution RiskAnalyst warns that the investment thesis depends on successful execution of pivotal studies, creating execution risk that could pressure the stock if trials miss endpoints or encounter delays.
Regulatory DependenceAnalyst cautions that favorable regulatory updates are required to realize the company’s growth plans, and adverse regulatory outcomes could significantly reduce projected market opportunities.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $46.48 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $4.89B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 33 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Nov 03, 2025. The company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $0.219 by $2.211.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.37.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 158,759,450 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $2.43 in its last earnings report, beating expectations of $0.219. Following the earnings report the stock price went down -3.134%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.60 (40.55% Upside)
$42.60 (40.55% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.38%
12-Months-Change
Fundamentals
Return on Equity
111.96%
Trailing 12-Months
Asset Growth
74.91%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TGTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, positive developments in clinical trials, and an increase in market presence and revenue guidance. However, there were challenges with increased operating expenses and limited ex-U.S. sales growth. Overall, the highlights significantly outweigh the lowlights.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$42.60
▲(40.55% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
7.30% Insiders
17.80% Mutual Funds
1.43% Other Institutional Investors
49.88% Public Companies and
Individual Investors